Teuza
49 Hahistadrut Avenue, Haifa, 31250, Israel
Overview
Founded in 1992, Teuza is a Venture capital fund (VC) publicly traded in the Tel Aviv stock exchange. Teuza invests in Venture companies in the fields of IT, software, communications, electronics, medical equipment and healthcare in all stages. Teuza's investments are usually in the range of $500,000-$4 million, sometimes in multiple rounds. Teuza's main interest is in companies that have breakthrough technologies, thus giving them an 'unfair advantage' in their fields, and a chance to become a world leader in their sector. Teuza's policy is to involve in our portfolio companies strategic partners from our broad business network, typically well-known multinational companies that bring added value. Teuza believes in a "hands on" approach to assist its portfolio companies. For that, it's involved in the ongoing management through: Board membership, active participation in setting strategy and tactics, recruitment of key positions, funding, budget decisions and more. Teuza's Chairman is Prof. Moshe Arens, Israel's former minister of defense, minister of foreign affairs and ambassador to the United States. Teuza is managed by Teuza management and development 1991 ltd, headed by its CEO, Mr. Avi Kerbs.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 4
Sector focus
- Financial Services
- Health Care
- Information Technology
- Venture Capital
Investment portfolio
- TytoCare
Participated · Series D · Apr 2020
TytoCare develops a clinician-grade handheld remote examination platform paired with FDA-cleared AI-powered software-as-a-medical-device algorithms to enable comprehensive remote physical exams. The company serves health systems, payers, and employer health programs and is positioning its platform for cardiopulmonary screening, oncology supportive care, and chronic disease management including CHF and COPD. TytoCare announced leadership appointments of Adam Pellegrini as CEO and Greg Orr as COO concurrent with its $25M+ growth round led by Insight Partners. The company intends to use the new capital to expand its AI algorithm pipeline, deepen integrations with health systems and payers, and accelerate go-to-market efforts. TytoCare is headquartered in New York and Netanya, Israel, and emphasizes FDA-cleared diagnostic fidelity as a competitive differentiator.